Despite these limitations, the researchers believe the study confirmed the efficacy and safety of bimekizumab and brodalumab ...

The company noted that the results further support the role of Sotyktu, the first TYK2 inhibitor available for patients living with moderate-to-severe plaque psoriasis, as a potential oral ...

“The initiation of the Phase 1b trial in subjects with moderate-to-severe plaque psoriasis represents a major step forward in advancing our novel and highly selective oral BET ...

With this approval, Celltrion will begin a global phase 3 clinical trial for CT-P55, a biosimilar of Cosentyx, involving 375 patients with plaque psoriasis. A comparative study will be conducted ...

Feb. 3, 2025 — Psoriasis is a chronic skin disease that manifests itself mainly with skin symptoms (dryness, itching, scaly skin, abnormal patches and plaques). It affects about 2% of the ...

Vyne Therapeutics has dosed the first participant in a randomised Phase Ib clinical trial of VYN202, an oral treatment for moderate-to-severe plaque psoriasis. The double-blind, placebo-controlled ...

There are many misconceptions about psoriasis—and a common one is that it is triggered by bad personal hygiene. However, ...

was arrested at a City Council meeting after speaking out against plans to install a plaque with references to President Trump’s slogan “Make America Great Again.” “Everyone is in favor of ...

He also had scaling plaques on his scalp ... A clinical diagnosis was made of psoriasis and he was prescribed clobetasol propionate ointment with salicylic acid 6% in petrolatum that should ...

“The initiation of the Phase 1b trial in subjects with moderate-to-severe plaque psoriasis represents a major step forward in advancing our novel and highly selective oral BET inhibitor, VYN202,” said ...

Psoriasis is a chronic autoimmune condition that occurs when the body makes new skin cells too quickly. Rather than sloughing off like normal, old skin cells accumulate and form dry, itchy plaques on ...

Highlights from "Deadline: White House." ...